Description
kisqali pricing
Kisqali is used to treat certain types of early, advanced, or metastatic HR-positive HER2-negative breast cancer in combination with an endocrine-based agent. It is an oral tablet taken once daily for 21 consecutive days out of a 28-day cycle. kisqali pricing
Kisqali (ribociclib) is a CDK4/6 inhibitor that works by blocking enzymes driving cell division. Combined with hormonal therapy such as letrozole or fulvestrant, it slows growth and shrinks estrogen receptor-positive breast tumors.
Kisqali gained FDA approval on March 13, 2017.
Side effects
Common side effects
The most common side effects of Kisqali in adults with early breast cancer are:
- Decreased white blood cell counts
- Decreased red blood cell counts
- Increased liver function tests
- Infections
- Increased kidney function tests
- Decreased platelet counts
- Nausea
- Headache
- Tiredness.
Reviews
There are no reviews yet.